Klaviyo (NYSE:KVYO – Get Free Report) and JFrog (NASDAQ:FROG – Get Free Report) are both computer and technology companies, but which is the superior investment? We will compare the two businesses ...

which the group expects to recognise as revenue in the second half of the financial year. The sales pipeline stands at £4.8m, including £3.4m in advanced negotiations. The group anticipates ...

Management reaffirmed full-year guidance, projecting 6%-8% recurring revenue growth and 8%-12% adjusted EPS growth. With a robust sales pipeline, strong equity position growth, and ongoing ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd ... To counter the ongoing decline in Eylea sales, Regeneron developed a higher dose (8 mg) of the drug ...

If approved, the company expects those drugs to generate peak sales between $1 billion and $3 billion each. Takeda certainly needs to pad out its pipeline given that the company’s lead product ...

“In 2024 we grew our business with four products in five indications globally, exceeding the updated revenue guidance we provided in August, and continuing our path toward profitability,” said ...

Additionally, BioMarin’s global footprint supports its strategy for continued revenue growth ... rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for ...

Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million ...

Management adjusted fiscal 2025 revenue guidance to a range of $2.07 billion to $2.11 billion, citing higher gross-to-net adjustments and potential tariff impacts. Adjusted EBITDA guidance was revised ...

“Building upon our foundation of strong and continued revenue growth for WAKIX, our multi-franchise pipeline has come into focus with value-creating catalysts expected each and every quarter ...